MannKind to Present at the Jefferies Global Healthcare Conference
Get Alerts MNKD Hot Sheet
Join SI Premium – FREE
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies London Healthcare Conference on Wednesday, November 19, at 6:30 am ET/11:30 am GMT.
The link to the live audio webcast of the session is available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.

For MannKind: Investor Relations Ana Kapor Email: [email protected] Media Relations Christie Iacangelo Email: [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services
- Best AI Crypto Coins August 2026: MemeToro, Chainlink and Virtuals Protocol in Focus
- Globalstar Confirms Successful Launch of All 8 HIBLEO-4 Replacement Satellites
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share